CYCCP
Income statement / Annual
Last year (2024), Cyclacel Pharmaceuticals, Inc.'s total revenue was $43.00 K,
a decrease of 89.76% from the previous year.
In 2024, Cyclacel Pharmaceuticals, Inc.'s net income was -$11.21 M.
See Cyclacel Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$43.00 K |
$420.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$150.00 K |
$0.00 |
$843.00 K |
$1.94 M |
| Cost of Revenue |
$6.00 K
|
$0.00
|
$32.00 K
|
$43.00 K
|
$20.00 K
|
$20.00 K
|
$4.33 M
|
$32.00 K
|
$9.48 M
|
$12.38 M
|
| Gross Profit |
$37.00 K
|
$420.00 K
|
-$32.00 K
|
-$43.00 K
|
-$20.00 K
|
-$20.00 K
|
-$4.18 M
|
-$32.00 K
|
-$8.63 M
|
-$10.44 M
|
| Gross Profit Ratio |
0.86
|
1
|
0
|
0
|
0
|
0
|
-27.85
|
0
|
-10.24
|
-5.37
|
| Research and Development Expenses |
$6.66 M
|
$19.16 M
|
$20.27 M
|
$15.48 M
|
$4.76 M
|
$4.66 M
|
$4.33 M
|
$4.24 M
|
$9.48 M
|
$12.38 M
|
| General & Administrative Expenses |
$5.39 M
|
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
$5.73 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$20.00 K
|
| Selling, General & Administrative Expenses |
$5.39 M
|
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
$5.75 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.30 M
|
$144.00 K
|
$891.00 K
|
$231.00 K
|
$682.00 K
|
$949.00 K
|
$0.00
|
$12.13 K
|
| Operating Expenses |
$12.05 M
|
$25.87 M
|
$27.66 M
|
$22.94 M
|
$10.64 M
|
$9.68 M
|
$9.70 M
|
$9.49 M
|
$14.99 M
|
$18.13 M
|
| Cost And Expenses |
$12.05 M
|
$25.87 M
|
$27.66 M
|
$22.94 M
|
$10.64 M
|
$9.68 M
|
$9.70 M
|
$9.49 M
|
$14.99 M
|
$18.13 M
|
| Interest Income |
$12.00 K
|
$266.00 K
|
$210.00 K
|
$16.00 K
|
$42.00 K
|
$224.00 K
|
$331.00 K
|
$118.00 K
|
$37.00 K
|
$9.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$6.00 K
|
$31.00 K
|
$32.00 K
|
$43.00 K
|
$20.00 K
|
$20.00 K
|
$29.00 K
|
$32.00 K
|
$133.00 K
|
$210.00 K
|
| EBITDA |
-$12.00 M |
-$25.42 M |
-$27.62 M |
-$22.69 M |
-$10.62 M |
-$9.66 M |
-$9.52 M |
-$9.46 M |
-$14.02 M |
-$15.96 M |
| EBITDA Ratio |
-279.02
|
-60.53
|
0
|
0
|
0
|
0
|
-63.46
|
0
|
-16.63
|
-8.21
|
| Operating Income Ratio |
-279.16
|
-60.6
|
0
|
0
|
0
|
0
|
-63.65
|
0
|
-16.79
|
-8.32
|
| Total Other Income/Expenses Net |
$10.00 K
|
-$98.00 K
|
$1.74 M
|
$204.00 K
|
$955.00 K
|
$556.00 K
|
$923.00 K
|
$1.03 M
|
$376.00 K
|
-$316.00 K
|
| Income Before Tax |
-$11.99 M
|
-$25.55 M
|
-$25.92 M
|
-$22.73 M
|
-$9.68 M
|
-$9.13 M
|
-$8.63 M
|
-$8.46 M
|
-$13.77 M
|
-$16.49 M
|
| Income Before Tax Ratio |
-278.93
|
-60.84
|
0
|
0
|
0
|
0
|
-57.5
|
0
|
-16.34
|
-8.48
|
| Income Tax Expense |
-$782.00 K
|
-$3.00 M
|
-$4.72 M
|
-$3.85 M
|
-$1.24 M
|
-$1.30 M
|
-$1.34 M
|
-$993.00 K
|
-$1.98 M
|
-$2.14 M
|
| Net Income |
-$11.21 M
|
-$22.56 M
|
-$21.20 M
|
-$18.89 M
|
-$8.45 M
|
-$7.83 M
|
-$7.29 M
|
-$7.47 M
|
-$11.79 M
|
-$14.34 M
|
| Net Income Ratio |
-260.74
|
-53.7
|
0
|
0
|
0
|
0
|
-48.59
|
0
|
-13.99
|
-7.38
|
| EPS |
-20.25 |
-424.17 |
-423.75 |
-476.08 |
-190.02 |
-143.88 |
-180.79 |
-279.14 |
-1032.85 |
-1585.98 |
| EPS Diluted |
-20.25 |
-424.17 |
-423.75 |
-476.08 |
-190.02 |
-143.88 |
-180.79 |
-279.14 |
-1032.85 |
-1585.98 |
| Weighted Average Shares Out |
$553.70 K
|
$53.18 K
|
$50.03 K
|
$39.67 K
|
$44.44 K
|
$54.41 K
|
$40.31 K
|
$26.76 K
|
$11.42 K
|
$9.04 K
|
| Weighted Average Shares Out Diluted |
$553.70 K
|
$53.18 K
|
$50.03 K
|
$39.67 K
|
$44.44 K
|
$54.41 K
|
$40.31 K
|
$26.76 K
|
$11.42 K
|
$9.04 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
